MOG (35-55): Benchmark Peptide for Experimental Autoimmune Encephalomyelitis Models

Executive Summary: MOG (35-55) is a truncated human myelin oligodendrocyte glycoprotein peptide widely used to induce EAE in rodents, the gold-standard model for multiple sclerosis (MS) research (Xu et al., 2025). It provokes strong T and B cell responses and triggers demyelinating disease upon administration with complete Freund's adjuvant (APExBIO). This peptide supports precise control of disease onset, severity, and relapse. MOG (35-55) modulates NADPH oxidase and MMP-9 activities, linking it to oxidative stress and matrix remodeling. Its well-characterized solubility and stability profile enables reproducible protocols for autoimmune and neuroinflammatory studies.

Biological Rationale

MOG (35-55) is a synthetic peptide comprising amino acids 35–55 of the human myelin oligodendrocyte glycoprotein (MOG), a member of the immunoglobulin superfamily predominantly expressed on the surface of oligodendrocytes in the central nervous system (Xu et al., 2025). The peptide is highly immunogenic in rodents, especially in C57BL/6 and HLA-DR2 transgenic mice, where it induces T cell-mediated demyelination resembling human MS. MOG (35-55) is routinely used to establish experimental autoimmune encephalomyelitis (EAE), the preeminent animal model for dissecting the immunopathogenesis of MS (see prior review). Unlike whole-protein immunization, the use of a defined peptide enables reproducible induction of disease and facilitates mechanistic studies targeting specific immune pathways.

Mechanism of Action of MOG (35-55)

MOG (35-55) acts as an autoantigen, triggering immune responses when presented by MHC class II molecules on antigen-presenting cells. Upon subcutaneous injection, typically emulsified with complete Freund's adjuvant (CFA), the peptide is processed and presented to CD4+ T cells, leading to their activation and expansion. These encephalitogenic T cells migrate to the central nervous system, where they recognize endogenous MOG. This recognition results in local inflammation, infiltration of immune cells, and demyelination (Xu et al., 2025). B cells are also activated, producing MOG-specific antibodies that contribute to pathology. In vitro, MOG (35-55) increases NADPH oxidase and MMP-9 activities, implicating oxidative stress and extracellular matrix remodeling in EAE pathogenesis (detailed mechanistic review). The disease course is dose-dependent and exhibits relapsing-remitting or chronic progressive forms, mirroring major features of human MS.

Evidence & Benchmarks

• Subcutaneous administration of 50–150 μg MOG (35-55) in C57BL/6 mice induces MS-like neurological symptoms and weight loss in a dose-dependent manner (Xu et al., 2025, Fig. 3A).
• MOG (35-55) elicits robust T and B cell responses, leading to CNS infiltration and extensive demyelination (APExBIO validation).
• In vitro, MOG (35-55) decreases protein concentration and increases NADPH oxidase and MMP-9 activity in a dose-dependent manner, indicating roles in oxidative stress and matrix remodeling (mechanistic summary).
• EAE induction with MOG (35-55) is highly reproducible and allows precise control of disease onset, severity, and relapse by varying peptide dose and immunization schedule (protocol guidance).
• PARP7 inhibition stabilizes STAT1/STAT2 and alleviates EAE severity in MOG (35-55)-induced models, highlighting new therapeutic targets for MS (Xu et al., 2025).

Applications, Limits & Misconceptions

MOG (35-55) is widely applied to study the immunopathology of MS, test immunomodulatory therapies, and dissect mechanisms of neuroinflammation. It enables high-throughput screening of candidate drugs and genetic interventions. APExBIO’s MOG (35-55) (SKU: A8306) is validated for reproducibility and batch consistency (product page), supporting both basic and translational research. This article extends the mechanistic coverage provided in previous reviews by integrating new data on STAT1/STAT2 regulation via PARP7, offering actionable insights for targeted intervention design.

Common Pitfalls or Misconceptions

• Not all mouse strains are susceptible: MOG (35-55) induces EAE primarily in strains such as C57BL/6 and HLA-DR2 transgenic mice; other strains may not respond or may exhibit different disease courses (Xu et al., 2025).
• Peptide solubility is solvent-dependent: MOG (35-55) is insoluble in ethanol and should be prepared in water or DMSO, with warming and sonication to maximize solubility (APExBIO).
• Stock stability is limited: Reconstituted peptide must be stored desiccated at -20°C and used promptly to avoid degradation.
• Not a spontaneous MS model: Disease induction requires active immunization; the model does not recapitulate spontaneous MS etiology.
• Immune response is adjuvant-dependent: Complete Freund's adjuvant is necessary for robust EAE induction; omission or substitution alters disease penetrance and kinetics.

Workflow Integration & Parameters

MOG (35-55) should be dissolved in sterile water at a concentration of 0.50 mg/mL, with warming and ultrasonic bath treatment to enhance solubility. For in vivo induction, subcutaneous injection of 50–150 μg per mouse, emulsified with complete Freund's adjuvant, is standard (A8306 kit protocol). Dose and schedule modulate disease onset and severity. Stock solutions are stable desiccated at -20°C for short-term use. In vitro, titration enables detailed analysis of NADPH oxidase and MMP-9 activity. For protocol optimization, see the strategic guide in this extended article, which updates practical considerations for translational MS research using APExBIO’s MOG (35-55).

Conclusion & Outlook

MOG (35-55) remains the benchmark peptide for EAE induction and multiple sclerosis modeling. Its defined sequence, robust immunogenicity, and well-documented performance underpin its status as a critical tool in neuroimmunology. Ongoing research, including mechanistic insights into PARP7-STAT1/STAT2 regulation, promises to refine our understanding of MS pathogenesis and identify new therapeutic entry points (Xu et al., 2025). APExBIO’s validated supply ensures experimental rigor and reproducibility, advancing both basic and translational investigations.